|
|
| | Fluphenazine decanoate Basic information |
| Product Name: | Fluphenazine decanoate | | Synonyms: | FluphenazineCecanoate;FLUPHENAZINEDECANATE;Decanoic acid, 2-[4-[3-[2-(trifluoromethyl) -10H-phenothiazin-10-yl]propyl]-1-piperazinyl]ethyl ester;Decanoic acid 2-[4-[3-(2-trifluoromethyl-10H-phenothiazin-10-yl)propyl]piperazin-1-yl]ethyl ester;Decanoic acid fluphenazine;2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-piperazinyl)ethyld;dapotumd;decanoicacid,2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl)-1-pipera | | CAS: | 5002-47-1 | | MF: | C32H44F3N3O2S | | MW: | 591.77 | | EINECS: | 225-672-4 | | Product Categories: | Organics;API | | Mol File: | 5002-47-1.mol |  |
| | Fluphenazine decanoate Chemical Properties |
| Melting point | 30-32° | | Boiling point | 658.1±55.0 °C(Predicted) | | density | 1.149±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol. | | pka | 7.32±0.10(Predicted) | | CAS DataBase Reference | 5002-47-1 |
| RIDADR | 3249 | | RTECS | HE0525000 | | HazardClass | 6.1(a) | | PackingGroup | II |
| | Fluphenazine decanoate Usage And Synthesis |
| Chemical Properties | Yellow Oil | | Uses | Fluphenazine Decanoate is used in psychotropic drug treatments like those relating to schizophrenia. Antipsychotic. | | Definition | ChEBI: Fluphenazine decanoate is the prodrug of fluphenazine, an antipsychotic drug used for the symptomatic management of psychosis in patients with schizophrenia. It has a role as a phenothiazine antipsychotic drug, a prodrug and a dopaminergic antagonist. It is a member of phenothiazines, a decanoate ester, an organofluorine compound and a N-alkylpiperazine. It is functionally related to a fluphenazine. | | Clinical Use | AntipsychoticSchizophrenia and other psychoses | | Drug interactions | Potentially hazardous interactions with other drugs Anaesthetics: enhanced hypotensive effect. Analgesics: increased risk of convulsions with
tramadol; enhanced hypotensive and sedative effects
with opioids. Anti-arrhythmics: increased risk of ventricular
arrhythmias with anti-arrhythmics that prolong
the QT interval; increased risk of ventricular
arrhythmias with amiodarone and dronedarone -
avoid; increased risk of ventricular arrhythmias with
disopyramide.Antibacterials: increased risk of ventricular
arrhythmias with delamanid and moxifloxacin -
avoid Antidepressants: increased risk of ventricular
arrhythmias with tricyclics, citalopram, escitalopram;
possible increased risk of convulsions with
vortioxetineAntiepileptics: antagonises anticonvulsant effect.Antimalarials: increased risk of ventricular
arrhythmias with artenimol with piperaquine and
artemether/lumefantrine - avoid.Antipsychotics: increased risk of ventricular
arrhythmias with droperidol, pimozide and
risperidone - avoid; avoid use of depot formulations
with clozapine (cannot be withdrawn quickly if
neutropenia occurs).Antivirals: increased risk of ventricular arrhythmias
with saquinavir - avoid; concentration possibly
increased with ritonavir.Anxiolytics and hypnotics: increased sedative effectsAtomoxetine: increased risk of ventricular
arrhythmias.Beta-blockers: enhanced hypotensive effect;
increased risk of ventricular arrhythmias with sotalolCytotoxics: increased risk of ventricular arrhythmias
with arsenic trioxideDiuretics: enhanced hypotensive effect.Lithium: increased risk of extrapyramidal side effects
and possibly neurotoxicity.Pentamidine: increased risk of ventricular
arrhythmias - avoid.Avoid with drugs that prolong the QT interval. | | Metabolism | The cytochrome P450 isoenzyme CYP2D6 is involved in
fluphenazine metabolism. |
| | Fluphenazine decanoate Preparation Products And Raw materials |
|